The global antidiabetics market size was valued at USD 105.03 billion in 2025 and is projected to grow from USD 115.73 billion in 2026 to USD 251.53 billion by 2034, registering a CAGR of 10.19% during the forecast period (2026-2034). North America dominated the antidiabetics market with a share of 39.16% in 2025.
Antidiabetics are pharmaceutical products control blood glucose levels and manage diabetes mellitus, including type 1 diabetes, type 2 diabetes, and other forms of diabetes. They are primarily classified under WHO ATC Code A10 – Drugs Used in Diabetes, which covers medicinal products used for blood-glucose regulation and diabetes management.
The antidiabetics market demand is driven by the obesity and sedentary lifestyles, aging population, and the need for long-term glycemic management. The expansion of healthcare access and diabetes screening programs in emerging economies further supports treatment adoption. The use of GLP-1 receptor agonists, SGLT2 inhibitors, combination therapies, and newer insulin formulations also contribute to the antidiabetics market growth.
Download a Free Sample To learn more about this report,
Shift Toward GLP-1 and GIP/GLP-1 Therapies
The antidiabetics market analysis shows a shift from primarily glucose-lowering treatment toward broader metabolic management, particularly among patients with obesity and related complications. For example, tirzepatide (Mounjaro) combines GIP and GLP-1 receptor activity and has become an important treatment option for adults with type 2 diabetes.
Adoption of Cardio-Kidney-Metabolic Treatment Strategies
Treatment decision are shifting toward therapies that simultaneously address diabetes and associated cardiovascular, renal, and metabolic risks. For example, SGLT2 inhibitors such as dapagliflozin and empagliflozin are used in appropriate patients with type 2 diabetes because of their established cardiovascular and kidney-related benefits.
Supply chain disruptions are expected to have a moderate impact on the antidiabetics market share, given its exposure to fluctuations in active pharmaceutical ingredients (APIs), insulin manufacturing inputs, and biologics production materials. The market is expected to experience a K-shaped recovery, as established pharmaceutical manufacturers stabilize with diversified manufacturing networks and strategic inventories. The market is expected to grow at a CAGR of 10.19%, but prolonged supply chain constraints could lower this by 2.0 percentage points, resulting in a growth of 8.19%. As supply conditions normalize, the antidiabetics market growth is expected to gradually return to approximately 10.19%.
The antidiabetics market forecasts investment/funding directed toward diabetes drug development, beta-cell regeneration technologies, and expansion of pharmaceutical production capacity.
Key Investment and Funding Activities in Antidiabetics Market, 2026
Caspian Therapeutics
USD 50 Million
In September 2026, Caspian Therapeutics launched with USD 50 million in financing led by BVF Partners. The funding will advance KO-7246, a menin inhibitor designed to increase pancreatic beta-cell mass and endogenous insulin production for Type 1 and Type 2 diabetes.
Syntax Bio
USD 14.4 Million
In June 2026, Syntax Bio announced an expanded Series A financing of USD 14.4 million, bringing total funding to more than USD 25 million. The financing supports its Cellgorithm platform and development of a pancreatic beta-cell therapy for Type 1 diabetes through preclinical proof-of-concept.
Novo Nordisk
USD 497 Million*
In March 2026, Novo Nordisk announced an investment to expand its manufacturing facility in Athlone, Ireland. The company announcement cited an investment of approximately USD 485 million.
BreezeBio
USD 60 Million
In February 2026, BreezeBio announced the close of a USD 60 million Series B financing to advance its genetic-medicine pipeline. Its lead program, BRZ-101, is designed to restore immune tolerance in Type 1 diabetes and was being advanced toward IND-enabling studies.
Increasing Demand for Early Combination Therapy and Rising Adoption of Oral Antidiabetic Formulations Drive Market Growth
The growing use of combination therapy is creating demand for antidiabetic medicines that can target multiple glucose-regulation pathways within a single treatment regimen. Fixed-dose combinations of metformin with DPP-4 inhibitors or SGLT2 inhibitors can simplify medication schedules and reduce pill burden for patients requiring sustained glycemic control. This is encouraging pharmaceutical manufacturers to expand combination-drug portfolios and develop formulations suited to long-term disease management.
Oral antidiabetic formulations is supporting demand for convenient, non-injectable treatment options, particularly among patients managing type 2 diabetes over extended periods. Advances in oral drug development, including SGLT2 inhibitors, DPP-4 inhibitors, and fixed-dose combinations, are broadening treatment choices while helping simplify medication schedules. These developments are encouraging pharmaceutical manufacturers to expand oral therapy portfolios and improve treatment convenience across different stages of diabetes management.
Dependence on Complex Cold-Chain Infrastructure and Low Diabetes Screening Rates Restrain Market Expansion
Dependence on temperature-controlled storage and transportation limits the availability of insulin and other temperature-sensitive biologic medicines in regions with weak healthcare logistics. Limited refrigeration capacity and unreliable electricity can increase distribution complexity and reduce treatment access in underserved markets.
Limited access to routine diabetes screening leaves many patients undiagnosed and outside the formal treatment pathway. Delayed identification reduces timely initiation of antidiabetic therapy, particularly in regions with weaker primary healthcare and diagnostic infrastructure.
Expansion of Home-Based Diabetes and Development of Temperature-Stable Insulin Formulations Offer Growth Opportunities
Home-based diabetes management creates opportunities for pharmaceutical companies to develop medicines and delivery formats suited to self-administration outside clinical settings. Manufacturers of insulin pens, prefilled injectors, oral therapies, and connected medication-delivery systems can capture additional value through patient-friendly treatment solutions.
Temperature-stable insulin formulations offer opportunities for pharmaceutical innovators targeting healthcare systems where refrigerated storage is difficult to maintain. Drug developers can expand their portfolios with formulations that simplify storage and transportation requirements while improving usability in resource-constrained settings. Companies developing advanced insulin formulations can establish new commercial opportunities across markets with limited cold-storage infrastructure.
Insulin dominated the drug class segment with a share of 22.5% in 2025, owing to its established role in glucose management across insulin-dependent diabetes and advanced stages of type 2 diabetes. The segment remains an important component of diabetes treatment because of the broad availability of different insulin formulations and delivery options.
The GLP-1 receptor agonists segment is anticipated to grow at a CAGR of 16.72% during the forecast period, fueled by increasing clinical use of therapies that support glycemic control alongside weight management.
Request Customizationto receive a tailored report.
In 2025, Type 2 had a share of 71.7% in the diabetes type segment, supported by the large patient population requiring long-term pharmacological management and the broad availability of oral and injectable glucose-lowering therapies.
Type 1 diabetes segment is projected to grow at a CAGR of 8.47% during the forecast period, supported by continued demand for lifelong insulin therapy and advances in insulin delivery systems. Improvements in insulin analogs, glucose monitoring, and automated insulin delivery are expected to support treatment management.
Oral dominated the route of administration segment in 2025, accounting for a share of 52.8%. This dominance is attributed to the convenience of oral dosing and the widespread availability of tablets across several established antidiabetic drug classes.
The subcutaneous segment is likely to witness a CAGR of 11.27% during the forecast period, propelled by the use of injectable therapies, particularly GLP-1 receptor agonists and insulin-based treatments.
By end-use industry, drug stores & retail pharmacies accounted for a dominant share of 48.7% in 2025, supported by their broad accessibility and established role in dispensing prescription and chronic-disease medicines.
The online pharmacies segment is expected to experience a growth rate of CAGR of 13.92% during the forecast period. Online channels provide greater convenience for patients requiring regular medicine refills and can simplify access to chronic-care treatments.
Speak to an Analystto discuss market opportunities.
The North America inspection equipment market accounted for a dominant share of 39.16% in 2025.
CMS has established 2027 Medicare Part D negotiated prices in the US for selected high-expenditure medicines, including Ozempic, Rybelsus, and Wegovy, with the negotiated price for a 30-day supply of the products. The 2027 Medicare Part D framework is expected to support broader access to high-value diabetes therapies through participating plans, pharmacies, and dispensing entities.
Diabetes Canada projects that the number of Canadians with diagnosed diabetes will increase from approximately 4.0 million in 2024 to 5.3 million by 2034, This supports demand for insulin, oral antidiabetic drugs, and newer glucose-lowering therapies.
Unlock Regional Insightsto access country-level data, & regional trends.
The Asia Pacific inspection equipment market is expected to grow at CAGR of 12.47% during the forecast period, showcasing the fastest growth.
Japan’s Ministry of Health, Labour and Welfare is also advancing its Health Japan 21 (Third Term) program, which targets the prevention of diabetes and its complications. This supports the need for ongoing disease management and glucose-lowering therapies.
China’s pharmaceutical policy framework is expected to strengthen domestic development and manufacturing capabilities for innovative medicines and biologic therapies. China’s State Council has set a 2035 target for stronger pharmaceutical innovation and global competitiveness, while regulatory reforms through 2027 are designed to improve the efficiency of drug review and approval and strengthen the pharmaceutical industry ecosystem.
National diabetes management initiatives in India are expected to strengthen access to affordable oral glucose-lowering medicines through protocol-based treatment and public-health delivery systems. WHO reported that more than 184,000 public healthcare facilities had adopted drug- and dose-specific treatment protocols and digital monitoring systems, supporting wider availability of standardized diabetes treatment.
The Europe antidiabetics market is expected to grow at a CAGR of 9.21% during the forecast period.
NHS England’s diabetes treatment program in the UK is expected to support continued improvements in structured diabetes treatment and medicine management across integrated care systems. National NHS planning emphasizes reducing variation in access and improving treatment outcomes, while the diabetes population in England is projected to reach 4.2 million by 2030.
Germany’s regulatory framework is strengthening the substitution of lower-cost biosimilar medicines through community pharmacies, which supports the use of economically efficient biological therapies. Under the G-BA framework, pharmacy substitution of eligible biologic medicines by lower-priced alternatives is permitted, with continued updates to the national biosimilar interchangeability framework. This policy direction is expected to encourage broader utilization of cost-efficient biologic treatments, including insulin-based therapies.
The Latin America antidiabetics market is expected to grow at a CAGR of 10.36 % during the forecast period. Brazil benefits from public pharmaceutical system to maintain demand for affordable diabetes medicines through centralized procurement and nationwide distribution. The Ministry of Health is responsible for purchasing and distributing human NPH and regular insulin to state and municipal health authorities.
Consolidated public procurement framework in Mexico is expected to strengthen the availability of essential medicines through coordinated purchasing by federal healthcare institutions. Government procurement guidelines cover the 2027–2028 purchasing cycles, while the national procurement system integrates institutions including IMSS, ISSSTE, IMSS-Bienestar, and Birmex to coordinate medicine requirements and distribution.
The Middle East & Africa antidiabetics market is expected to grow at a CAGR of 10.74% during the forecast period. WHO’s UAE health system framework emphasizes improved access to quality essential health services, medicines, diagnostics, and medical devices supporting the development of advanced diabetes-care pathways.
Primary Healthcare Essential Medicines List and Standard Treatment Guidelines in South Africa provide a structured framework for managing common conditions at clinics and community health centers, including endocrine conditions. The National Department of Health is continuing the 2025–2029 review cycle for primary healthcare treatment guidelines and essential medicines, supporting ongoing integration of evidence-based medicines.
The antidiabetics market competitive landscape is moderately concentrated, with competition spread across multinational pharmaceutical companies. Key players such as Novo Nordisk, Eli Lilly, Sanofi, Merck, and AstraZeneca are estimated to account for over 60% of the global diabetes value market share.
Established pharmaceutical companies compete through oral antidiabetic formulations and diabetes therapeutics. Emerging and specialized players in the antidiabetic market compete through novel mechanisms of action, targeted therapies, and competitive differentiation across the market.
September 2026: Roche announced positive Phase II results for enicepatide, an investigational once-weekly dual GLP-1/GIP receptor agonist.
March 2026: Dr. Reddy’s Laboratories launched Obeda (semaglutide injection) following DCGI approval, marking the company's entry into the GLP-1 receptor agonist segment with a once-weekly prefilled pen for type 2 diabetes
Customize This Report to Match Your Strategic Objectives
Author's Details
Research Experts
The Straits Research Team is a group of experienced researchers, analysts, and industry professionals dedicated to delivering reliable, insightful, and well-structured market intelligence. With expertise across multiple sectors and domains, the team combines extensive research, data analysis, and industry knowledge to provide a clear understanding of evolving markets and business environments.
The team focuses on identifying key market trends, emerging opportunities, technological developments, competitive landscapes, and changing industry dynamics. Through a thoughtful and research-driven approach, it aims to provide valuable insights that help businesses, investors, and decision-makers better understand their industries and make informed strategic decisions.
Asbestosis Treatment Market Size, Forecast, Demand, 2034
Brain Tumor Treatment Market Size, Forecast, Demand, 2034
Ibuprofen Market Size, Share, Growth, Analysis, Report, 2034
Medical Aesthetics Market Size, Share, Growth, Analysis, 2034
Byler Disease Market Size, Forecast, Demand, Opportunities, 2034
Complement Inhibitors Market Size, Share, Growth, Analysis, 2034
We are featured on:
sales@straitsresearch.com